Epstein Secrets

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

on WHO-AM Des Moines, IA (10/22) and WHO- AM Des Moines, IA (10/22). Stocks Finish Higher On Hopes Of Additional Stimulus. Reuters (10/22, Chavez- Dreyfuss) reports stocks finished higher Thursday "as investors cheered the prospect of more fiscal stimulus to support a pandemic-damaged U.S. economy." The

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

rs <https://www.reuters.com/article/us-usa- stocks/wall-street-closes-higher-trade-choppy-as-u-s-stimulus-talks-eyed-idUSIGEIN2771H9> (10/22, Chavez- Dreyfuss) reports stocks finished higher Thursday "as investors cheered the prospect of more fiscal stimulus to support a pandemic-damaged U.S. economy." The

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

WHO-AMVi Des Moines, IA (10/22) and WHO-AMVi Des Moines, IA (10/22). Stocks Finish Higher On Hopes Of Additional Stimulus. Reuters (10/22, Chavez- Dreyfuss) reports stocks finished higher Thursday "as investors cheered the prospect of more fiscal stimulus to support a pandemic-damaged U.S. economy." The